This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Aragon Pharmaceuticals, Inc.. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: John Lee Sensintaffar: Innovator in Androgen Receptor Therapy
Introduction
John Lee Sensintaffar is a notable inventor based in Poway, California. He has made significant contributions to the field of androgen receptor therapy, particularly in developing methods and compositions that enhance treatment options for patients.
Latest Patents
Sensintaffar holds a patent for "Methods and compositions for determining resistance to androgen receptor therapy." This patent describes modified androgen receptor polypeptides that are resistant to inhibition by androgen receptor inhibitors. The patent also details compositions, combinations, and kits that utilize these modified polypeptides. Furthermore, it outlines methods for using these polypeptides as screening agents to identify and design third-generation androgen receptor modulators. These modulators are crucial for inhibiting the activity of the modified polypeptides and include pharmaceutical compositions and medicaments aimed at treating diseases, including castration-resistant prostate cancers.
Career Highlights
Sensintaffar is associated with Aragon Pharmaceuticals, Inc., where he continues to advance research in androgen receptor therapies. His work is pivotal in developing innovative solutions for conditions mediated by androgen receptors.
Collaborations
He has collaborated with notable colleagues, including James David Joseph and Jeffrey H. Hager, contributing to the advancement of research in his field.
Conclusion
John Lee Sensintaffar's innovative work in androgen receptor therapy exemplifies the impact of targeted research in medicine. His contributions are vital for improving treatment options for patients with hormone-dependent cancers.